Skip to main content
Stanislav Lazarev, MD, Radiation Oncology, New York, NY

StanislavLazarevMD

Radiation Oncology New York, NY

Assistant Professor, Mount Sinai Hospital and New York Proton Center, New York, NY

Dr. Lazarev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lazarev's full profile

Already have an account?

  • Office

    1184 5th Ave
    New York, NY 10029
    Phone+1 646-872-9186
    Fax+1 212-410-7194

Summary

  • Dr. Stanislav (Stas) Lazarev, MD, is an Assistant Professor and the Associate Program Director of the Radiation Oncology Residency Program at the Icahn School of Medicine at Mount Sinai in New York City. He provides patient care at both Mount Sinai Hospital and the New York Proton Center.

    Dr. Lazarev specializes in the personalized treatment of central nervous system (CNS) tumors, including primary and metastatic brain and spinal cord tumors in both children and adults, leptomeningeal disease (LMD), pediatric tumors, and the re-irradiation of CNS, thoracic, and hepatobiliary tumors. His other major focus is the radiation treatment of primary thoracic and hepatobiliary tumors using proton beam therapy. His clinical expertise includes proton craniospinal irradiation (CSI) for LMD, proton re-irradiation, proton radiotherapy for pediatric cancers, and low-dose re-irradiation for recurrent pediatric diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma, H3 K27-altered WHO Grade 4.

    In recognition of his dedication to compassionate and effective communication, Dr. Lazarev was honored with the Cullman Family Award for Excellence in Provider Communication in 2024. Dr. Lazarev was among 89 Mount Sinai providers who ranked in the top 5% nationally in provider communication, as measured by the Press Ganey 2023 patient experience surveys.

    Dr. Lazarev’s commitment to education has also been recognized with the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award in both 2022 and 2024.

    Dr. Lazarev’s work reflects his dedication to advancing cancer care across all settings, from local clinical practice to national and international initiatives, ensuring that his expertise benefits diverse patient populations while driving innovations in radiation oncology.

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiResidency, Radiation Oncology, 2015 - 2019
  • University of Vermont College of Medicine
    University of Vermont College of MedicineClass of 2014
  • University of California, Berkeley
    University of California, BerkeleyB.A., Biochemistry and Molecular Biology, Magna Cum Laude, 2009
  • Pyatigorsk State Linguistic University
    Pyatigorsk State Linguistic UniversityB.A. Candidate, Theory and Practice of Translation and Interpretation (Russian/English/Spanish) , 2004
  • Instituto Cervantes
    Instituto CervantesDiploma of Spanish as a Second Language (DELE), 2003

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2019 - 2026
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Best of ASTRO Abstract 2017
  • Summer Undergraduate Research Fellowship Scholarship Yale University, 2008
  • Alumni Leadership Award Scholarship University of California, Berkeley, 2007-2008
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck Irradiation  
    Lazarev S, Gupta V, Ghiassi-Nejad Z, Miles B, Scarborough B, Misiukiewicz KJ, Reckson B, Sheu R, Bakst R, Advances Radiat Oncol
  • Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10-years of Follow-Up  
    Lazarev S, Thompson M, Stone N, Stock R, BJU Int, 1/1/2018
  • Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck Irradiation  
    Lazarev S, Gupta V, Ghiassi-Nejad Z, Miles B, Scarborough B, Misiukiewicz KJ, Reckson B, Sheu R, Bakst R, Advances Radiat Oncol, 1/1/2018
  • Join now to see all

Abstracts/Posters

  • Discontinuation of Curative Head and Neck Irradiation: Etiologies and Outcomes.
    Lazarev S, Ghiassi-Nejad Z, Gupta V, Miles B, Scarborough B, Misiukiewicz K, Reckson B, Sheu R, Bakst R, Multidisciplinary Head And Neck Cancers Symposium, Scottsdale, AZ, 1/1/2018
  • Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck Irradiation.
    Lazarev S, Gupta V, Ghiassi-Nejad Z, Scarborough B, Reckson B, Sheu R, Bakst R, 59th American Society for Radiation Oncology Annual Meeting, San Diego, CA, 1/1/2017
  • Clinical Outcomes after Premature Discontinuation of Curative Head and Neck Irradiation.
    Lazarev S, Ghiassi-Nejad Z, Gupta V, Misiukiewicz K, Miles B, Sheu R, Bakst R, 59th American Society for Radiation Oncology Annual Meeting, San Diego, CA, 1/1/2017
  • Join now to see all

Lectures

  • Oncological Emergencies: What is the Role of Radiation Therapy? 
    Oakland, CA - 1/5/2018
  • Low-dose-rate Brachytherapy as Monotherapy for High-Risk Prostate Cancer: 15-year Outcomes Data. 
    Orlando, FL - 1/1/2018
  • "Bath Salts": The New Designer Drug of Abuse 
    Burlington, VT - 1/1/2012
  • Join now to see all

Other

Press Mentions

  • Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?
    Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?December 2nd, 2024
  • Mount Sinai Researchers Publish Critical Examination of New Brain Tumor Drug
    Mount Sinai Researchers Publish Critical Examination of New Brain Tumor DrugSeptember 23rd, 2024
  • Suny Downstate Hematology Oncology Fellowship
    Suny Downstate Hematology Oncology FellowshipJune 11th, 2021

Professional Memberships

Other Languages

  • Catalan, Portuguese, Russian, Spanish, French, Hebrew